On Jan. 2, Hookipa inked a non-binding agreement that would have created a merged company with Poolbeg via an all-stock ...

This recognition follows another recent honor for Mr. Kras, who was named a finalist for the Entrepreneur Of The Year® 2024 New Jersey Award by Ernst & Young (EY US). This award celebrates innovative ...

Medical experts discuss strategies for managing adverse events associated with KRAS-targeted therapies, addressing monitoring ...

Groups partner on research project to test innovative new treatment for KRAS-mutant cancer being developed at Hebrew ...

Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC. See why I rate CRDF stock as a ...

An investigational therapy significantly shrank lung cancer tumors that are notoriously resistant to treatment by encouraging ...

A discovery of how to target mutated proteins in tumors made a decade ago never matured into a surefire way of destroying ...

Scientists at UC San Francisco have developed a revolutionary cancer treatment that precisely targets tumors with radiation ...

Phase I clinical trials are the first step in testing a new treatment or combination of treatments. These trials often ...

Genprex’s (GNPX) research collaborators at a major cancer research center in Houston, Texas have published a new study which used the company’s ...